These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27797288)

  • 21. 'Crazy Monkey' poisons man and dog: Human and canine seizures due to PB-22, a novel synthetic cannabinoid.
    Gugelmann H; Gerona R; Li C; Tsutaoka B; Olson KR; Lung D
    Clin Toxicol (Phila); 2014 Jul; 52(6):635-8. PubMed ID: 24905571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hospitalisation associated with use of the synthetic cannabinoid K2.
    Glue P; Al-Shaqsi S; Hancock D; Gale C; Strong B; Schep L
    N Z Med J; 2013 Jun; 126(1377):18-23. PubMed ID: 23831873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabinoid hyperemesis: a case series.
    Donnino MW; Cocchi MN; Miller J; Fisher J
    J Emerg Med; 2011 Apr; 40(4):e63-6. PubMed ID: 19765941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of the 2016 Psychoactive Substances Act on synthetic cannabinoid use within the homeless population: Markets, content and user harms.
    Ralphs R; Gray P; Sutcliffe OB
    Int J Drug Policy; 2021 Nov; 97():103305. PubMed ID: 34146792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic cannabinoid intoxication: a case series and review.
    Harris CR; Brown A
    J Emerg Med; 2013 Feb; 44(2):360-6. PubMed ID: 22989695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids.
    Hopkins CY; Gilchrist BL
    J Emerg Med; 2013 Oct; 45(4):544-6. PubMed ID: 23890687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and Correlates of Any and Frequent Synthetic Cannabinoid Use in a Representative Sample of High School Students.
    Clements-Nolle K; Lensch T; Larson S; Yang W
    Subst Use Misuse; 2016 Jul; 51(9):1139-46. PubMed ID: 27191966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From "herbal highs" to the "heroin of cannabis": Exploring the evolving discourse on synthetic cannabinoid use in a Norwegian Internet drug forum.
    Bilgrei OR
    Int J Drug Policy; 2016 Mar; 29():1-8. PubMed ID: 26860324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repeated Thrombosis After Synthetic Cannabinoid Use.
    Raheemullah A; Laurence TN
    J Emerg Med; 2016 Nov; 51(5):540-543. PubMed ID: 27595371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening of mental health and substance users in frequent users of a general Swiss emergency department.
    Vu F; Daeppen JB; Hugli O; Iglesias K; Stucki S; Paroz S; Canepa Allen M; Bodenmann P
    BMC Emerg Med; 2015 Oct; 15():27. PubMed ID: 26452550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacological properties and dependence liabilities of synthetic cannabinoids].
    Funada M
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2010 Jun; 45(3):167-74. PubMed ID: 20681249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Changing Face of Synthetic Cannabinoids in Texas.
    Maxwell JC
    J Psychoactive Drugs; 2018; 50(4):281-286. PubMed ID: 30321129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. College students and use of K2: an emerging drug of abuse in young persons.
    Hu X; Primack BA; Barnett TE; Cook RL
    Subst Abuse Treat Prev Policy; 2011 Jul; 6():16. PubMed ID: 21745369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.
    Chase PB; Hawkins J; Mosier J; Jimenez E; Boesen K; Logan BK; Walter FG
    Clin Toxicol (Phila); 2016; 54(1):14-9. PubMed ID: 26653952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.
    Palamar JJ; Su MK; Hoffman RS
    Am J Drug Alcohol Abuse; 2016; 42(1):39-47. PubMed ID: 26678258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics and Treatment of Patients with Clinical Illness Due to Synthetic Cannabinoid Inhalation Reported by Medical Toxicologists: A ToxIC Database Study.
    Monte AA; Calello DP; Gerona RR; Hamad E; Campleman SL; Brent J; Wax P; Carlson RG;
    J Med Toxicol; 2017 Jun; 13(2):146-152. PubMed ID: 28397128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe Illness Associated with Reported Use of Synthetic Cannabinoids - Mississippi, April 2015.
    Kasper AM; Ridpath AD; Arnold JK; Chatham-Stephens K; Morrison M; Olayinka O; Parker C; Galli R; Cox R; Preacely N; Anderson J; Kyle PB; Gerona R; Martin C; Schier J; Wolkin A; Dobbs T
    MMWR Morb Mortal Wkly Rep; 2015 Oct; 64(39):1121-2. PubMed ID: 26447715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New psychoactive substance use among regular psychostimulant users in Australia, 2010-2015.
    Sutherland R; Peacock A; Whittaker E; Roxburgh A; Lenton S; Matthews A; Butler K; Nelson M; Burns L; Bruno R
    Drug Alcohol Depend; 2016 Apr; 161():110-8. PubMed ID: 26880592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Zombie" Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York.
    Adams AJ; Banister SD; Irizarry L; Trecki J; Schwartz M; Gerona R
    N Engl J Med; 2017 Jan; 376(3):235-242. PubMed ID: 27973993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic cannabinoid and marijuana exposures reported to poison centers.
    Forrester MB; Kleinschmidt K; Schwarz E; Young A
    Hum Exp Toxicol; 2012 Oct; 31(10):1006-11. PubMed ID: 22859662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.